DRKS00000071进行中（未招募）3 期
Phase III, multi-center, randomized, double-blind, placebo-controlled study for treatment of juvenile ankylosing spondylitis with Adalimumab
Asklepios Klinik Sankt Augustin0 个研究点目标入组 32 人开始时间: 2009年2月6日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 32
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized controlled study
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 12 Years 至 18 Years（—）
- 性别
- All
入选标准
- •IN1Parents / legal guardian are willing to participate in the study and signed voluntarily the Informed Consent form.
- •-IN2Parents / legal guardian are willing to actively supervise storage and administration of study drug and to ensure that the time of each dose is accurately recorded in the subject's diary.
- •-IN3Patient and parents / legal guardian agree to comply with study requirements and are able to be at the clinic for all required study visits.
- •-IN4Patient is at least 12 years old and has not reached his 18th birthday.
- •-IN5The weight of the patient is > 30 kg.
- •-IN6IN FEMALE PATIENT IN WHOM MENARCHE HAS OCCURRED
- •>Negative serum pregnancy test prior to administration of study medication.
- •>Willingness to use an adequate method of contraception
- •Adequate contraception can include abstinence if the investigator deems appropriate.
- •-IN7Patient has a diagnosis of juvenile ankylosing spondylitis, i.e.
- •Abilateral active sacroiliitis confirmed by magnetic resonance imaging is present
- •Bunilateral active sacroiliitis confirmed by magnetic resonance imaging is present, and patient has active peripheral joint disease restricted to the lower extremities (hip, knee, ankle)
- •AND at least 1 clinical criterion is fulfilled:
- •1.limitation of lumbar spine motion in all three planes
- •2.pain or history of pain at the dorsolumbar junction of the lumbar spine
- •3.limitation of chest expansion to 2.5 cm or less at the level of the fourth intercostal space.
- •-IN8Patient has active disease, i.e.
- •1.spinal inflammation score of at least 3
- •AND at least 2 of the following domains:
- •2.back pain score of at least 3
- •3.patient global assessment of disease activity of at least 3
- •4.physical function score of at least 3.
- •-IN9The disease has been refractory to at least two different non-steroidal antiphlogistic drugs given at appropriate dosage and for appropriate period of time.
- •-IN10Patient has not been treated with either etanercept or infliximab or adalimumab or anakinra at any time for any period.
- •-IN11Patient is able and willing to self-administer sc injections or has a suitable person at his disposal to administer sc injections.
- •-IN12Patient must be evaluated for active or latent TB infection according to the instructions of the protocol. If applicable: Guidelines regarding the treatment of latent TB must be followed prior to the administration of study medication.
排除标准
- •-EX1Patient has been diagnosed to have systemic onset of JRA / JIA or has active systemic features including fever or rash.
- •-EX2Patient has active uveitis within a period of 4 weeks prior to the first administration of study medication.
- •-EX3Pregnant or breast feeding female.
- •-EX4Female not willing to use appropriate contraception or sexual abstinence.
- •-EX5Chronic or active infectious disease, especially patient is positive for the hepatitis B surface antigen.
- •-EX6Preceding severe infectious disease during a period of 3 months prior to the first administration of study medication.
- •-EX7Preceding diagnosis of tuberculosis or any opportunistic infection including herpes zoster at any time.
- •-EX8Any preceding diagnosis of malignancy.
- •-EX9Patient has a history of any chronic disease other than JAS, JRA / JIA, especially chronic renal disease, liver disease, hematological, gastrointestinal, pulmonary, cardiological or neurological disease, which in the opinion of the investigator may influence the efficacy or safety of the study medication or which in the opinion of the investigator leads to an unacceptable risk for the patient if he participates in the study.
- •-EX10Patient had a significant illness during a period of 4 weeks prior to the first administration of study medication other than JAS-related.
- •-EX11Patient is abusing alcohol or drugs.
- •-EX12Patient has been treated with antimalarials, gold salts, sulphasalazine, azathioprine, penicillamine, leflunomide, cyclosporine A, intravenous immunoglobulin, or methotrexate within 4 weeks prior to the first administration of study medication, or plans to begin the intake of these drugs.
- •-EX13Patient has been exposed to etanercept or infliximab or adalimumab or anakinra before receiving the first dose of study medication.
- •-EX14Patient has begun the intake or changed the dose regimen of oral corticosteroids within 4 weeks before Screening, doses of up to 0.2 mg/kg or 10 mg prednisone or equivalent per day, whichever is less, are allowed.
- •-EX15Patient plans to change dosing of oral corticosteroids within the study period.
- •-EX16Patient has received i.v., i.m., i.a. or soft tissue injections of corticosteroids within 4 weeks before first administration of study medication.
- •-EX17Patient has previously been admitted to this study.
- •-EX18Patient has been treated with any other investigational agent within 30 days or 5 half-lifes of the agent, whichever is longer, prior to the screening evaluation.
- •-EX19Patient has been treated with any investigational biologic agent within 6 months prior to the screening evaluation.
- •-EX20Demonstration of clinically significant deviations in any of the following laboratory parameters:
- •>platelet count < 100.000/mm3
- •>total white cell count < 4000 cells/mm3
- •>neutrophils < 1000 cells/mm3
- •>hematocrit < or = 24%
- •>AST or ALT or serum bilirubin > 2x the upper limit of normal
- •>glomerular filtration rate GFR < 90 mL/min / 1.73 m2 BSA
- •[GFR (mL/min / 1.73 m2 BSA) = 0.55 x height (cm) / plasma creatinine (mg/dL)]
- •-EX21Patient has a history of an expanding CNS neoplasm, active CNS infection, demyelinating disease, degenerative neurological disease or any progressive CNS disease.
- •-EX22Patient has a poorly controlled diabetes.
- •-EX23Any concurrent medical condition which would, in the investigator's opinion, compromise the patient's ability to tolerate the study drug or would make the patient unable to comply with the
研究者
相似试验
已完成
3 期
ABDALA Clinical Study - Phase IIICOVID-19SARS-CoV2Disease PreventionCoronavirus InfectionsSARS VirusCoronaviridae InfectionsBetacoronavirusRPCEC00000359Center for Genetic Engineering and Biotechnology (CIGB), in Havana.48,290
尚未招募
3 期
Clinical trial to compare the efficacy and safety between the combination of dorzolamide hydrochloride (2%) + brimonidine tartrate (0.2%) + timolol maleate (0.5%) and COMBIGAN® (combination of 0.2% brimonidine tartrate + 0.5% timolol maleate) in reducing ocular pressure in adult patients with primary open-angle glaucoma or high pressure in the eyesopen-angle glaucomaocular hypertensionglaucoma suspicionC11.525.381.407C11.525H40.1H40.0Primary open-angle glaucomaRBR-3crsfjaboratório Daudt Oliveira Ltda.
已完成
3 期
Prevention of neonatal sepsis in low birth weight infantsCTRI/2019/05/019197Indian Council of Medical Research Hqrs6,144
进行中（未招募）
不适用
Phase III, multi-center, randomized, double blind, placebo-controlled study for treatment of juvenile ankylosing spondylitis with Adalimumab - Humira StudyMedDRA version: 10Level: LLTClassification code 10002556Term: <Manually entered code. Term in E.1.1>Juvenile ankylosing spondylitisEUCTR2007-003358-27-DECenter of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin
进行中（未招募）
不适用
Phase III, multicentre, double-blind, randomised, placebo-controlled, study to assess the efficacy of V0337 SO 01A suspension 10ml 4 times a day during 7 days on 2 parallel groups of patients suffering from symptoms of gastro-oesophageal reflux disease (GORD)GORD-related symptomsMedDRA version: 9.1Level: LLTClassification code 10017885Term: Gastrooesophageal reflux diseaseEUCTR2008-002562-60-FRPIERRE FABRE MEDICAMENT